Roche receives FDA clearance with CLIA waiver and CE Mark for its first point-of-care test for diagnosing Bordetella infections, including whooping cough (pertussis)

The point-of-care test delivers PCR-accurate results in just 15 minutes, enabling healthcare providers to act quickly and ...

Devyser Diagnostics AB: Devyser strengthens U.S. market presence with CMS pricing for PrenatalDetect RHD test

Devyser today announced that the Centers for Medicare & Medicaid Services (CMS) has issued its final pricing determination for the company's PrenatalDetect RHD test (CPT 0536U) at $192. The non-invasi ...